Overview

Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis

Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This study is a single-center, prospective, nonrandom, single-arm trial.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Guangdong ProCapZoom Biosciences Co., Ltd.